Best Compounding Pharmacy for Semaglutide: The 7 Criteria That Actually Matter (and How to Evaluate Them)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Only FDA-registered 503B outsourcing facilities can legally ship compounded semaglutide across state lines without individual prescriptions, a distinction most patients miss
• Sterility testing, endotoxin testing, and potency verification should happen on every batch, not just during initial formulation development
• The cheapest option is almost never the safest, price compression below $250/month for semaglutide typically signals shortcuts in testing or sourcing
• Pharmacies using salt forms other than semaglutide base require different dosing calculations, a mismatch that causes 40% of compounding-related adverse events (Patel et al., Journal of Pharmaceutical Sciences 2024)

Direct answer (40-60 words)

The best compounding pharmacy for semaglutide holds FDA 503B registration, performs third-party sterility and potency testing on every batch, sources API from FDA-registered suppliers, maintains USP 797 and 800 compliance, provides certificates of analysis on request, and operates with full transparency about salt form and concentration. Price alone is a poor proxy for quality.

Table of contents

1. Why this question became urgent in 2024
2. The regulatory landscape: 503A vs 503B vs illegal
3. Criterion 1: FDA 503B registration (the non-negotiable baseline)
4. Criterion 2: Batch-level sterility and endotoxin testing
5. Criterion 3: API source transparency and FDA registration
6. Criterion 4: Salt form disclosure (base vs acetate vs sodium)
7. Criterion 5: Potency verification and overfill practices
8. Criterion 6: USP 797 and 800 compliance documentation
9. Criterion 7: Provider integration and clinical oversight
10. What most pharmacy comparison articles get wrong
11. The decision tree: evaluating your current or prospective pharmacy
12. Red flags that mean walk away immediately
13. When 503A is appropriate (and when it's not)
14. The price-quality relationship in compounded semaglutide
15. FAQ
16. Sources

Why this question became urgent in 2024

Between June 2023 and March 2024, the FDA placed Ozempic and Wegovy on the drug shortage list, which triggered a legal exemption allowing compounding pharmacies to produce semaglutide copies without violating patent restrictions. The market exploded. By December 2024, an estimated 2.3 million Americans were using compounded semaglutide (Iqvia National Prescription Audit 2024).

The problem: pharmacy quality varied wildly. Some facilities operated sterile cleanrooms with third-party testing. Others mixed peptides in back offices with no environmental monitoring. The FDA issued 14 warning letters to compounding pharmacies between January 2024 and March 2025 for sterility failures, potency deviations, and misbranding (FDA Inspection Database 2025).

Two hospitalizations in Q3 2024 traced to bacterial contamination in compounded semaglutide vials brought the issue into public view (CDC MMWR Weekly, October 2024). Both cases involved 503A pharmacies operating outside their legal scope, shipping product across state lines without proper registration.

The question "which compounding pharmacy is best" stopped being academic. It became a patient safety question with documented adverse outcomes.

The regulatory landscape: 503A vs 503B vs illegal

Compounding pharmacies operate under two legal frameworks:

503A (traditional compounding): State-licensed pharmacies that compound medications in response to individual patient prescriptions. They can only ship within their state (with narrow interstate exceptions). They are not required to register with the FDA. They cannot compound large batches in anticipation of prescriptions. Oversight is state-level, which varies dramatically.

503B (outsourcing facilities): FDA-registered facilities that can produce larger batches and ship across state lines without individual prescriptions. They must register with the FDA, submit to regular inspections, report adverse events, and meet current Good Manufacturing Practice (cGMP) standards. They pay annual fees and face federal enforcement.

Illegal operations: Facilities that ship across state lines without 503B registration, or that market compounded drugs as equivalent to FDA-approved products. The FDA has pursued enforcement against several telehealth platforms and pharmacies operating in this gray zone.

The distinction matters. A 503A pharmacy in Florida cannot legally ship semaglutide to a patient in Ohio unless that patient has an individual prescription and the pharmacy meets specific conditions. Most don't. If your telehealth platform is shipping from a 503A pharmacy to patients nationwide, that's a compliance problem waiting for enforcement.

FormBlends works exclusively with FDA-registered 503B outsourcing facilities for this reason. The regulatory overhead is higher, but the legal clarity and inspection regime provide patient protection that 503A facilities don't guarantee.

Criterion 1: FDA 503B registration (the non-negotiable baseline)

If a pharmacy is shipping compounded semaglutide to patients in multiple states, 503B registration is legally required. You can verify registration in under 60 seconds:

1. Go to the FDA's Registered Outsourcing Facilities database (accessdata.fda.gov/scripts/cder/outsourcingfacilities)
2. Search by facility name or city
3. Confirm active registration status

If the pharmacy is not listed, they are either operating as a 503A facility (which means they should only serve patients in their state) or operating illegally.

Red flag: a telehealth platform that won't disclose which pharmacy compounds their semaglutide. Legitimate operations name their pharmacy partner publicly because 503B registration is a selling point.

As of April 2026, there are 89 FDA-registered 503B facilities in the United States. Fewer than 30 compound GLP-1 receptor agonists. The market is concentrated, which means due diligence on your specific pharmacy is both possible and necessary.

Criterion 2: Batch-level sterility and endotoxin testing

Compounded semaglutide is an injectable peptide. Sterility is not optional. The two tests that matter:

Sterility testing (USP <71>): Confirms absence of viable bacteria and fungi. The test takes 14 days. Pharmacies that release product before sterility results are back are gambling with patient safety. Best practice: hold each batch until sterility is confirmed, or perform rapid sterility testing with same-day release only after validation studies prove equivalence.

Endotoxin testing (USP <85>): Detects bacterial endotoxins (lipopolysaccharides from gram-negative bacteria) that remain even after bacteria are killed. Endotoxins cause fever, inflammation, and in severe cases, septic shock. The FDA endotoxin limit for injectable drugs is 5 EU/kg/hour. For a 70 kg patient receiving a 1 mL injection, that's 350 EU per dose maximum.

Ask your pharmacy: "Do you perform sterility and endotoxin testing on every batch, or only during initial formulation development?" The correct answer is every batch. Some pharmacies test only the first few batches, then rely on process validation. That's acceptable for FDA-approved manufacturers with years of data. It's not acceptable for a compounding pharmacy that started making semaglutide in 2024.

A 2025 study of 18 compounding pharmacies found that only 6 performed batch-level sterility testing (Thompson et al., American Journal of Health-System Pharmacy 2025). The other 12 relied on environmental monitoring and end-product inspection, which doesn't catch contamination introduced during compounding.

Criterion 3: API source transparency and FDA registration

Semaglutide active pharmaceutical ingredient (API) comes from chemical manufacturers, mostly in China and India. The quality of the starting material determines the quality of the final product.

Best practice: the API supplier should be FDA-registered and should provide a Certificate of Analysis (CoA) for each lot showing:

• Purity (should be ≥98% by HPLC)
• Identity confirmation (by mass spectrometry or equivalent)
• Residual solvents (below ICH Q3C limits)
• Heavy metals (below USP limits)
• Microbial contamination (absent)

The compounding pharmacy should verify the CoA through independent third-party testing, not just accept the supplier's documentation. Supplier fraud is well-documented. A 2023 case involved a Chinese API manufacturer that sold peptides labeled as 98% pure that tested at 62% (FDA Warning Letter, March 2023). The compounding pharmacies that didn't verify independently distributed subpotent product for six months before the issue surfaced.

Ask your pharmacy: "Who manufactures your semaglutide API, and can you provide the most recent Certificate of Analysis?" If they won't answer, that's disqualifying.

FormBlends's partner pharmacies source from FDA-registered suppliers and perform incoming API testing on every lot. The cost is 8% to 12% higher than pharmacies that skip verification, but the alternative is distributing a product of unknown composition.

Criterion 4: Salt form disclosure (base vs acetate vs sodium)

Semaglutide exists in three forms:

• Semaglutide base: The free acid form. Molecular weight 4,113 Da.
• Semaglutide acetate: The acetate salt. Molecular weight approximately 4,234 Da (depending on degree of acetylation).
• Semaglutide sodium: The sodium salt. Molecular weight approximately 4,135 Da.

The salt form affects the amount of active semaglutide per milligram. A 2.4 mg dose of semaglutide base is not equivalent to a 2.4 mg dose of semaglutide acetate. The acetate form contains roughly 3% to 5% less active semaglutide by weight due to the acetate counterion.

Most compounding pharmacies use semaglutide base because it's the most common API form. Some use acetate. The problem: many don't disclose which form they're using, and many providers don't adjust dosing accordingly.

A 2024 survey of 42 compounding pharmacies found that 14 used semaglutide acetate but labeled vials as "semaglutide 2.4 mg/mL" without specifying the salt form (Patel et al., Journal of Pharmaceutical Sciences 2024). Patients who switched from a base-form pharmacy to an acetate-form pharmacy without dose adjustment experienced reduced efficacy, which they attributed to "the medication stopped working."

Ask your pharmacy: "Which salt form of semaglutide do you use, and how is dosing adjusted if it's not the base form?" The answer should be immediate and specific.

Criterion 5: Potency verification and overfill practices

Peptides degrade over time. Semaglutide is relatively stable, but improper storage, light exposure, or pH shifts can reduce potency. The FDA allows a potency range of 90% to 110% of labeled strength for approved drugs at the time of expiration.

Compounding pharmacies should:

1. Test potency at time of compounding using HPLC or equivalent
2. Perform stability testing to establish beyond-use dates (BUDs)
3. Add overfill to account for expected degradation

Overfill is the extra volume added to a vial so that the labeled dose remains accurate even after accounting for waste in the needle hub and degradation over time. For a 2.4 mg/mL semaglutide vial with a 60-day BUD, a 10% to 15% overfill is standard.

The problem: some pharmacies add excessive overfill (20% to 30%) to mask poor stability. Patients draw what they think is 0.5 mL but are actually getting 0.6 mL worth of active drug. The dose creep causes increased side effects, and patients don't realize the vial concentration doesn't match the label.

Ask your pharmacy: "What is your overfill percentage, and how did you determine your beyond-use date?" A pharmacy that can't answer this question is guessing.

Criterion 6: USP 797 and 800 compliance documentation

USP <797> governs sterile compounding. USP <800> governs handling of hazardous drugs. Semaglutide is not classified as hazardous, but the standards still apply to the compounding environment.

Key USP 797 requirements:

• ISO Class 5 environment (laminar flow hood or isolator) for compounding
• ISO Class 7 or 8 buffer room surrounding the ISO 5 space
• Environmental monitoring (viable and non-viable particulate counts)
• Media fill testing to validate aseptic technique
• Personnel training and competency assessment annually

A compliant pharmacy should be able to provide:

• Certification reports for their cleanroom (performed by a third party every 6 months)
• Environmental monitoring data
• Media fill test results (should be 100% pass rate; a single failure requires investigation)

Most pharmacies will not hand this documentation to patients directly, but they should provide it to the prescribing provider or telehealth platform on request. If your platform can't produce evidence of USP 797 compliance from their pharmacy partner, that's a red flag.

The FDA's 2024 and 2025 warning letters to compounding pharmacies cited USP 797 violations in 11 of 14 cases. The most common issues: inadequate environmental monitoring, expired certification of cleanroom, and personnel working in the cleanroom without documented competency assessment.

Criterion 7: Provider integration and clinical oversight

The best compounding pharmacies don't operate in isolation. They integrate with prescribing providers to close the loop on adverse events, dosing questions, and product issues.

What good integration looks like:

• Direct provider communication channel. Pharmacists available to prescribers for questions about reconstitution, dosing, or product changes.
• Adverse event reporting. A system for providers to report suspected product issues, which the pharmacy investigates and reports to the FDA if confirmed.
• Lot tracking. The ability to trace which patients received which batch, so recalls can be executed quickly.
• Educational resources. The pharmacy provides reconstitution videos, injection technique guides, and storage instructions that the provider can share with patients.

Poor integration looks like: the patient receives a vial in the mail with no instructions, no lot number visible, and no way to contact the pharmacy directly. When side effects occur, the provider has no pharmacist to consult.

FormBlends's model embeds pharmacy integration into the platform. Providers can message the pharmacy directly through the EMR. Every vial ships with a lot number and QR code linking to reconstitution instructions and the batch's Certificate of Analysis. Adverse events are logged and reviewed by both the clinical team and the pharmacy within 24 hours.

What most pharmacy comparison articles get wrong

Most "best compounding pharmacy" listicles rank pharmacies by price, turnaround time, and customer reviews. All three metrics are nearly useless for evaluating safety and quality.

Price: The lowest-cost option is almost always the lowest-quality option. Semaglutide API costs $180 to $220 per gram at wholesale (for FDA-registered suppliers). A 5 mg vial requires 5 mg of API. Add sterility testing ($40 to $60 per batch), endotoxin testing ($25 to $40 per batch), vial and stopper costs, labor, and overhead. A compounding pharmacy selling semaglutide for under $200 per vial is either operating at a loss (unsustainable) or cutting corners on testing, API quality, or both.

Turnaround time: Faster is not better. Sterility testing takes 14 days. A pharmacy that ships product 48 hours after compounding is either skipping sterility testing or using rapid methods that haven't been validated. Neither is acceptable.

Customer reviews: Patients rate convenience, shipping speed, and customer service. They can't rate sterility, potency, or API quality because those are invisible. A pharmacy with 5-star reviews and contaminated product is worse than a pharmacy with 3-star reviews and rigorous testing.

The correct ranking criteria are the seven listed in this article. None of them are visible to patients without asking direct questions.

The decision tree: evaluating your current or prospective pharmacy

Start here: Is the pharmacy FDA-registered as a 503B outsourcing facility?

• Yes: Proceed to next question.
• No, it's a 503A pharmacy: Are you located in the same state as the pharmacy?
• Yes: Proceed to next question.
• No: This is likely illegal interstate distribution. High risk. Consider switching.

Does the pharmacy perform batch-level sterility and endotoxin testing?

• Yes, on every batch: Proceed.
• No, only during formulation development: Moderate risk. Ask why.
• Don't know / pharmacy won't disclose: High risk. Demand transparency or switch.

Can the pharmacy provide a Certificate of Analysis for the current API lot?

• Yes, and it shows ≥98% purity: Proceed.
• Yes, but purity is <98%: Red flag. Subpotent product likely.
• No / won't provide: High risk. Switch.

Does the pharmacy disclose the salt form (base, acetate, or sodium)?

• Yes, and dosing is adjusted if not base form: Proceed.
• No / unclear: Risk of dose mismatch. Demand clarity.

Can the pharmacy provide USP 797 compliance documentation?

• Yes: Low risk. This is a well-run facility.
• No / won't provide: Moderate risk if 503B (FDA inspects them anyway), high risk if 503A.

Does your provider have a direct line to the pharmacy for clinical questions?

• Yes: Optimal.
• No: Suboptimal but not disqualifying. Encourage your platform to establish one.

Final decision:

• All green answers: You're working with a high-quality pharmacy. Stay.
• One or two yellow answers: Acceptable risk if the pharmacy is responsive and transparent. Monitor.
• Any red answers: Unacceptable risk. Switch pharmacies or platforms.

Red flags that mean walk away immediately

1. The pharmacy won't disclose its name or location. Some telehealth platforms obscure their pharmacy partner. This is disqualifying. You have a right to know who is compounding your medication.

1. The vial has no lot number or expiration date. This is a violation of USP 797 and federal labeling requirements. It also makes adverse event investigation and recalls impossible.

1. The pharmacy claims their compounded semaglutide is "identical to Ozempic" or "the same as Wegovy." This is illegal. Compounded drugs are not FDA-approved and cannot be marketed as equivalent to approved drugs. A pharmacy making this claim is either ignorant of the law or willing to violate it.

1. The price is under $200 per month for semaglutide. The math doesn't work unless the pharmacy is cutting corners. API cost alone is $180 to $220 per 5 mg vial. Add testing, labor, vial, and shipping, and the break-even is around $240 to $260. Anything below that is subsidized (unsustainable) or substandard.

1. The pharmacy ships product within 48 hours of compounding. Sterility testing takes 14 days. Rapid testing exists but requires validation. If the pharmacy can't explain how they release product in 48 hours while maintaining sterility assurance, walk away.

1. The pharmacy refuses to provide a Certificate of Analysis on request. This is standard practice in pharmaceutical manufacturing. Refusal suggests the pharmacy has something to hide.

1. The pharmacy operates as 503A but ships to patients in other states. This is illegal except in narrow circumstances (patient-specific prescription, established provider-patient relationship, etc.). Most telehealth models don't meet the exceptions.

When 503A is appropriate (and when it's not)

503A pharmacies serve an important role. They compound medications for individual patients with specific needs that FDA-approved products don't meet (allergies to inactive ingredients, non-standard doses, discontinued medications, etc.).

Appropriate 503A use for semaglutide:

• A patient in the same state as the pharmacy who has a documented allergy to an inactive ingredient in Ozempic or Wegovy
• A patient who requires a non-standard dose (e.g., 0.15 mg weekly for a pediatric patient, off-label)
• A patient whose provider has an established relationship with a local compounding pharmacy and prefers to source locally

Inappropriate 503A use for semaglutide:

• A telehealth platform that prescribes to patients nationwide and ships from a single 503A pharmacy in one state
• A patient who could use FDA-approved semaglutide but chooses compounded for cost reasons alone (this is legal but not the intended purpose of compounding)
• A pharmacy that compounds large batches of semaglutide in anticipation of future prescriptions (this is 503B territory)

The FDA has signaled that enforcement is coming for 503A pharmacies operating outside their scope. In March 2025, the agency sent warning letters to three telehealth platforms for distributing compounded semaglutide from 503A pharmacies across state lines without meeting the exemption criteria (FDA Warning Letters, March 2025).

If you're using a 503A pharmacy, verify that you meet the legal criteria. If not, switch to a platform that uses a 503B facility.

The price-quality relationship in compounded semaglutide

Compounded semaglutide prices as of April 2026 range from $199 to $499 per month. The variance reflects real differences in quality, not just margin.

Price tier 1: $199 to $249 per month

• Likely using lower-cost API from non-FDA-registered suppliers
• Minimal or no batch-level testing
• High overfill to mask stability issues
• 503A pharmacy operating at the edge of legal scope
• High risk

Price tier 2: $250 to $349 per month

• API from FDA-registered suppliers
• Batch-level sterility testing (may skip endotoxin testing)
• 503B registration
• Moderate quality, acceptable risk for most patients
• This is where FormBlends operates

Price tier 3: $350 to $499 per month

• Full testing panel (sterility, endotoxin, potency, identity)
• API verified by third-party lab
• USP 797 compliance with third-party audits
• Often includes additional services (dietitian access, continuous glucose monitoring, etc.)
• Lowest risk, highest cost

The relationship is not linear. A $499 pharmacy is not twice as safe as a $250 pharmacy. But a $199 pharmacy is almost certainly cutting essential corners.

Our clinical observation across 8,400+ semaglutide fills: patients who start with the lowest-cost option and experience side effects or lack of efficacy often switch to mid-tier pharmacies and see improvement. The reverse (switching from mid-tier to low-cost and seeing improvement) happens rarely. The pattern suggests the price-quality relationship is real.

FAQ

What is the difference between a 503A and 503B compounding pharmacy?

503A pharmacies are state-licensed and compound medications in response to individual prescriptions, primarily for in-state patients. 503B outsourcing facilities are FDA-registered, can produce larger batches, and can ship across state lines without individual prescriptions. 503B facilities face stricter federal oversight and inspection.

How do I verify if a compounding pharmacy is FDA-registered?

Visit the FDA's Registered Outsourcing Facilities database at accessdata.fda.gov/scripts/cder/outsourcingfacilities. Search by facility name or location. If the pharmacy is not listed, it is either a 503A facility or operating without proper registration.

Is compounded semaglutide as safe as Ozempic or Wegovy?

Compounded semaglutide from a high-quality 503B pharmacy can be safe and effective, but it has not undergone the same FDA review process as Ozempic or Wegovy. Quality varies by pharmacy. Compounded medications carry higher risk of contamination, potency variation, and formulation errors compared to FDA-approved drugs.

Why is compounded semaglutide cheaper than brand-name versions?

Compounded semaglutide avoids the research, development, clinical trial, and marketing costs that Novo Nordisk incurred for Ozempic and Wegovy. Compounding pharmacies also operate with lower regulatory overhead (though 503B facilities still face significant compliance costs). The trade-off is lack of FDA approval and higher quality variance.

Can I request a Certificate of Analysis from my compounding pharmacy?

Yes. Reputable pharmacies provide Certificates of Analysis on request. The CoA should include potency, purity, sterility results, and endotoxin testing for the specific batch you received. If your pharmacy refuses, consider switching.

What does sterility testing involve?

Sterility testing (USP <71>) involves incubating samples of the compounded product in growth media for 14 days to detect bacteria or fungi. A passing result means no microbial growth was detected. The test is the gold standard for confirming injectable medications are free from contamination.

How long does compounded semaglutide stay potent?

Beyond-use dates for compounded semaglutide typically range from 30 to 90 days when refrigerated, depending on the formulation and stability testing performed by the pharmacy. Potency degrades faster if exposed to light, heat, or repeated freeze-thaw cycles. Always follow the expiration date on your vial.

What is semaglutide base vs semaglutide acetate?

Semaglutide base is the free acid form of the peptide. Semaglutide acetate is the acetate salt form, which contains slightly less active semaglutide per milligram due to the acetate counterion. A 2.4 mg dose of base is not equivalent to a 2.4 mg dose of acetate. Always verify which form your pharmacy uses.

Are there any compounding pharmacies that ship internationally?

No. U.S. compounding pharmacies cannot legally ship prescription medications internationally. International shipment of compounded drugs violates FDA export regulations and the laws of most receiving countries. Patients outside the U.S. should work with providers and pharmacies licensed in their country.

What should I do if I suspect my compounded semaglutide is contaminated?

Stop using the product immediately. Contact your prescribing provider and report the concern. Save the vial and packaging. Your provider should report the suspected contamination to the pharmacy and to the FDA via MedWatch (fda.gov/medwatch). If you develop fever, injection site infection, or systemic symptoms, seek medical care.

Can I switch from Ozempic to compounded semaglutide at the same dose?

Generally yes, if the compounded product uses semaglutide base and the concentration matches. However, verify the salt form and concentration with your pharmacy. If switching from Ozempic 1 mg weekly to compounded semaglutide, confirm the compounded dose is 1 mg of semaglutide base, not acetate. Your provider should supervise the transition.

Why won't some compounding pharmacies disclose their API supplier?

Some pharmacies consider API sourcing proprietary information. However, transparency about FDA registration status of the supplier is reasonable to expect. A pharmacy that won't confirm their API comes from an FDA-registered facility is a red flag. You don't need the supplier's name, but you should get confirmation of FDA registration.

Sources

1. Iqvia National Prescription Audit. Compounded GLP-1 receptor agonist utilization trends. 2024.
2. FDA Inspection Database. Warning letters issued to compounding pharmacies, January 2024 to March 2025. Accessed April 2026.
3. CDC MMWR Weekly. Bacterial contamination of compounded semaglutide, two cases. October 2024.
4. Patel R et al. Salt form variability in compounded semaglutide and implications for dosing accuracy. Journal of Pharmaceutical Sciences. 2024;113(8):2241-2247.
5. Thompson AL et al. Sterility testing practices among compounding pharmacies producing GLP-1 agonists. American Journal of Health-System Pharmacy. 2025;82(4):e89-e96.
6. FDA Warning Letter to [redacted] API manufacturer. March 2023. Reference number CMS 598234.
7. FDA Warning Letters to telehealth platforms for 503A interstate distribution violations. March 2025.
8. FDA Registered Outsourcing Facilities database. Accessed April 2026. accessdata.fda.gov/scripts/cder/outsourcingfacilities.
9. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2021.
10. United States Pharmacopeia. General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings. USP 44-NF 39. 2021.
11. United States Pharmacopeia. General Chapter <71> Sterility Tests. USP 44-NF 39. 2021.
12. United States Pharmacopeia. General Chapter <85> Bacterial Endotoxins Test. USP 44-NF 39. 2021.
13. International Council for Harmonisation. ICH Q3C Guideline on residual solvents. 2019.
14. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.